Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes

Cancer Discovery

Volumn 3, Issue 4, 2013, Pages 458-469

  Pedersen, Malin ^a   Küsters Vandevelde, Heidi V N ^d   Viros, Amaya ^a   Groenen, Patricia J T A ^e   Sanchez Laorden, Berta ^a   Gilhuis, Jacobus H ^f   van Engen van Grunsven, Ilse A ^e   Renier, Willy ^d   Schieving, Jolanda ^e   Niculescu Duvaz, Ion ^b   Springer, Caroline J ^b   Küsters, Benno ^e   Wesseling, Pieter ^d,e,g   Blokx, Willeke A M ^e   Marais, Richard ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f REINIER DE GRAAF HOSPITAL   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; DEXAMETHASONE; MANNITOL; PHENYTOIN; TAMOXIFEN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APHASIA; ARTICLE; CASE REPORT; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOLOGY; DNA EXTRACTION; DNA SEQUENCE; HEMIPLEGIA; HISTOLOGY; HUMAN; HYPERPIGMENTATION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE N RAS; PRESCHOOL CHILD; RISK FACTOR; RNA EXTRACTION; SEIZURE; SOMATIC MUTATION; WESTERN BLOTTING;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, RAS; HUMANS; MALE; MELANOCYTES; MELANOMA; MICE; MICE, INBRED C57BL;

EID: 84877680589     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0464     Document Type: Article

References (40)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-7.
2. Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, et al. Genetic and morphologic features for melanoma classifi cation. Pigment Cell Melanoma Res 2010; 23: 763-70.
3. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 2009; 145: 427-34.
4. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998; 83: 1664-78.
5. Seddon JM, Gragoudas ES, Glynn RJ, Egan KM, Albert DM, Blitzer PH. Host factors, UV radiation, and risk of uveal melanoma. A casecontrol study. Arch Ophthalmol 1990; 108: 1274-80.
6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
7. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6.
8. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602.
9. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-9.
10. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-3.
11. Brat DJ, Giannini C, Scheithauer BW, Burger PC. Primary melanocytic neoplasms of the central nervous systems. Am J Surg Pathol 1999; 23: 745-54.
12. Allcutt D, Michowiz S, Weitzman S, Becker L, Blaser S, Hoffman HJ, et al. Primary leptomeningeal melanoma: an unusually aggressive tumor in childhood. Neurosurgery 1993; 32: 721-9.
13. Makin GW, Eden OB, Lashford LS, Moppett J, Gerrard MP, Davies HA, et al. Leptomeningeal melanoma in childhood. Cancer 1999; 86: 878-86.
14. Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: defi nition and review of the literature. J Am Acad Dermatol 1991; 24: 747-55.
15. Shah KN. The risk of melanoma and neurocutaneous melanosis associated with congenital melanocytic nevi. Semin Cutan Med Surg 2010; 29: 159-64.
16. Pavlidou E, Hagel C, Papavasilliou A, Giouroukos S, Panteliadis C. Neurocutaneous melanosis: report of three cases and up-to-date review. J Child Neurol 2008; 23: 1382-91.
17. Kusters-Vandevelde HV, Klaasen A, Kusters B, Groenen PJ, van Engenvan Grunsven IA, van Dijk MR, et al. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2009; 119: 317-23.
18. Murali R, Wiesner T, Rosenblum MK, Bastian BC. GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol 2012; 123: 457-9.
19. Gessi M, Hammes J, Lauriola L, Dorner E, Kirfel J, Kristiansen G, et al. GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 2012 Jul 3. doi:10.1111/j 1365-2990.2012.01288.
20. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994; 131: 72-7.
21. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007; 127: 179-82.
22. Kovalyshyn I, Braun R, Marghoob A. Congenital melanocytic naevi. Australas J Dermatol 2009; 50: 231-40.
23. Powell MB, Hyman P, Bell OD, Balmain A, Brown K, Alberts D, et al. Pigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinogen 1995; 12: 82-90.
24. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009; 15: 294-303.
25. Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010; 70: 5549-57.
26. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-defi cient background. Cancer Res 2005; 65: 4005-11.
27. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544-52.
28. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997; 11: 2822-34.
29. Larue L, Beermann F. Cutaneous melanoma in genetically modifi ed animals. Pigment Cell Res 2007; 20: 485-97.
30. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
31. Dhomen N, Da Rocha Dias S, Hayward R, Ogilvie L, Hedley D, Delmas V, et al. Inducible expression of (V600E) Braf using tyrosinasedriven Cre recombinase results in embryonic lethality. Pigment Cell Melanoma Res 2010; 23: 112-20.
32. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-8.
33. Yajima I, Belloir E, Bourgeois Y, Kumasaka M, Delmas V, Larue L. Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genesis 2006; 44: 34-43.
34. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 2012; 14: 882-90.
35. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A 2003; 100: 1221-5.
36. Hacker E, Irwin N, Muller HK, Powell MB, Kay G, Hayward N, et al. Neonatal ultraviolet radiation exposure is critical for malignant melanoma induction in pigmented Tpras transgenic mice. J Invest Dermatol 2005; 125: 1074-7.
37. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-77.
38. Delmas V, Martinozzi S, Bourgeois Y, Holzenberger M, Larue L. Cre-mediated recombination in the skin melanocyte lineage. Genesis 2003; 36: 73-80.
39. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29: 19-24.
40. Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 2011; 20: 715-27.